S
1.98
-0.01 (-0.50%)
| Previous Close | 1.99 |
| Open | 2.00 |
| Volume | 5,989 |
| Avg. Volume (3M) | 46,187 |
| Market Cap | 4,156,732 |
| Price / Book | 3.06 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -3.44 |
| Total Debt/Equity (MRQ) | 144.16% |
| Current Ratio (MRQ) | 1.79 |
| Operating Cash Flow (TTM) | -5.24 M |
| Levered Free Cash Flow (TTM) | -2.49 M |
| Return on Assets (TTM) | -61.69% |
| Return on Equity (TTM) | -186.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Shuttle Pharmaceuticals Holding | - | - |
Stockmoo Score
0.3
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.25 |
|
Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 41.62% |
| % Held by Institutions | 1.72% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Sep 2024 | Announcement | Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma |
| 11 Sep 2024 | Announcement | Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing |
| 05 Sep 2024 | Announcement | Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease |
| 04 Sep 2024 | Announcement | Shuttle Pharma Provides Second Quarter 2024 Corporate Update |
| 28 Aug 2024 | Announcement | Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement |
| 26 Aug 2024 | Announcement | Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) |
| 14 Aug 2024 | Announcement | Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |